Sage Capital Advisors llc Increases Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Sage Capital Advisors llc lifted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 19.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 715 shares of the pharmaceutical company’s stock after purchasing an additional 114 shares during the quarter. Sage Capital Advisors llc’s holdings in Vertex Pharmaceuticals were worth $318,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. Activest Wealth Management purchased a new position in Vertex Pharmaceuticals during the first quarter valued at approximately $25,000. Clal Insurance Enterprises Holdings Ltd raised its position in Vertex Pharmaceuticals by 450.0% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 45 shares in the last quarter. Mascagni Wealth Management Inc. purchased a new position in Vertex Pharmaceuticals during the fourth quarter valued at approximately $31,000. Flaharty Asset Management LLC purchased a new position in Vertex Pharmaceuticals during the first quarter valued at approximately $32,000. Finally, Mpwm Advisory Solutions LLC purchased a new position in Vertex Pharmaceuticals during the fourth quarter valued at approximately $40,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Trading Down 0.7%

VRTX stock opened at $394.53 on Friday. The business’s fifty day moving average price is $422.66 and its 200 day moving average price is $453.56. Vertex Pharmaceuticals Incorporated has a 12-month low of $362.50 and a 12-month high of $519.88. The company has a market capitalization of $101.15 billion, a PE ratio of 28.20 and a beta of 0.44.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, topping the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company had revenue of $2.94 billion for the quarter, compared to the consensus estimate of $2.90 billion. During the same quarter in the prior year, the business earned ($12.83) EPS. Vertex Pharmaceuticals’s revenue was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Bruce I. Sachs purchased 5,000 shares of the business’s stock in a transaction on Wednesday, August 6th. The shares were bought at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the acquisition, the director directly owned 45,000 shares in the company, valued at $17,535,600. This trade represents a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

VRTX has been the topic of several research analyst reports. Truist Financial set a $490.00 price objective on Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 5th. Raymond James Financial started coverage on Vertex Pharmaceuticals in a research note on Tuesday, September 2nd. They issued a “market perform” rating on the stock. Royal Bank Of Canada lowered their price target on Vertex Pharmaceuticals from $430.00 to $405.00 and set a “sector perform” rating on the stock in a research note on Tuesday, August 5th. UBS Group set a $553.00 price target on Vertex Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 5th. Finally, Wells Fargo & Company raised Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $460.00 price target on the stock in a research note on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and thirteen have assigned a Hold rating to the stock. Based on data from MarketBeat, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $496.05.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.